Literature DB >> 17445789

Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure Results from the International Collaborative of NT-proBNP (ICON) Study.

Aaron L Baggish1, Roland van Kimmenade, Antoni Bayes-Genis, Mark Davis, John G Lainchbury, Chris Frampton, Yigal Pinto, Mark A Richards, James L Januzzi.   

Abstract

BACKGROUND: Hemoglobin and amino-terminal pro-brain natriuretic peptide (NT-proBNP) are both independent predictors of mortality in patients with chronic HF. Their combined predictive power for mortality in the setting of acute HF is uncertain.
METHODS: In an international prospective cohort design, we evaluated the relationships between hemoglobin, NT-proBNP, and 60-day mortality in 690 patients with acute HF.
RESULTS: The median hemoglobin for the entire cohort was 13.0 g/dL (interquartile range 11.6-14.3). The WHO criterion for anemia was met by 44% (n=305). The 60-day mortality rate for anemic patients was 16.4% vs. 8.8% in non-anemic patients (p<0.001). Anemia was an independent predictor of short-term mortality (OR=1.72, 95% CI=1.05-2.80, p=0.03), as was a NT-proBNP concentration >5180 pg/mL (OR=2.32, 95% CI=1.36-3.94 p=0.002). Consideration of four risk groups: not anemic/low NT-proBNP (reference group, n=220), anemic/low NT-proBNP (n=152), not anemic/high NT-proBNP (n=165), and anemic/high NT-proBNP (n=153) revealed respective 60-day mortality rates of 5.0% (referent), 9.2% (OR=1.93, 95% CI=0.85-4.36; p=0.12), 13.9% (OR=3.07, 95% CI=1.45-6.50, p=0.003), and 23.5% (OR=5.84, 95% CI=2.87-11.89, p<0.001).
CONCLUSIONS: Anemia was common in this cohort of subjects with acute HF and was related to adverse short-term outcome. Integrated use of hemoglobin and NT-proBNP measurements provides powerful additive information and is superior to the use of either in isolation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17445789     DOI: 10.1016/j.cca.2007.03.010

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review.

Authors:  Pasqualina L Santaguida; Andrew C Don-Wauchope; Mark Oremus; Robert McKelvie; Usman Ali; Stephen A Hill; Cynthia Balion; Ronald A Booth; Judy A Brown; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

2.  Prevalence and prognostic role of anaemia in patients with acute heart failure and preserved or depressed ventricular function.

Authors:  Luigi Tarantini; Fabrizio Oliva; Silvia Cantoni; Giovanni Cioffi; Virginia Agnoletto; Gianfranco Alunni; Francesca De Cian; Andrea Di Lenarda; Donata Lucci; Giovanni Pulignano; Laura Scelsi; Aldo Pietro Maggioni; Luigi Tavazzi
Journal:  Intern Emerg Med       Date:  2011-05-05       Impact factor: 3.397

Review 3.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

Review 4.  Anemia and the potential role of erythropoiesis-stimulating agents in heart failure.

Authors:  Haroon A Faraz; Syed F Zafar; Jalal K Ghali
Journal:  Curr Heart Fail Rep       Date:  2008-06

Review 5.  The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes.

Authors:  Yi-Da Tang; Stuart D Katz
Journal:  Heart Fail Rev       Date:  2008-02-02       Impact factor: 4.214

6.  Validity of Amino Terminal pro-Brain Natiuretic Peptide in a Medically Complex Elderly Population.

Authors:  Mazhar A Afaq; Azadeh Shoraki; Oleg Ivanov; Janardhan Srinivasan; Lawrence Bernstein; Stuart W Zarich
Journal:  J Clin Med Res       Date:  2011-07-26

Review 7.  Biomarkers for the diagnosis and management of heart failure.

Authors:  Vincenzo Castiglione; Alberto Aimo; Giuseppe Vergaro; Luigi Saccaro; Claudio Passino; Michele Emdin
Journal:  Heart Fail Rev       Date:  2021-04-14       Impact factor: 4.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.